In contrast to the continuous increase in survival rates for many cancer entities, colorectal cancer (CRC) and pancreatic cancer are predicted to be ranked among the top 3 cancer-related deaths in the European Union by 2025. Especially, fighting metastasis still constitutes an obstacle to be overcome in CRC and pancreatic cancer. As described by Fearon and Vogelstein, the development of CRC is based on sequential mutations leading to the activation of proto-oncogenes and the inactivation of tumour suppressor genes. In pancreatic cancer, genetic alterations also attribute to tumour development and progression. Recent findings have identified new potentially important transcription factors in CRC, among those the activating transcription factor 2 (ATF2). ATF2 is a basic leucine zipper protein and is involved in physiological and developmental processes, as well as in tumorigenesis. The mutation burden of ATF2 in CRC and pancreatic cancer is rather negligible; however, previous studies in other tumours indicated that ATF2 expression level and subcellular localisation impact tumour progression and patient prognosis. In a tissue- and stimulus-dependent manner, ATF2 is activated by upstream kinases, dimerises and induces target gene expression. Dependent on its dimerisation partner, ATF2 homodimers or heterodimers bind to cAMP-response elements or activator protein 1 consensus motifs. Pioneering work has been performed in melanoma in which the dual role of ATF2 is best understood. Even though there is increasing interest in ATF2 recently, only little is known about its involvement in CRC and pancreatic cancer. In this review, we summarise the current understanding of the underestimated 'cancer gene chameleon' ATF2 in apoptosis, epithelial-to-mesenchymal transition and microRNA regulation and highlight its functions in CRC and pancreatic cancer. We further provide a novel ATF2 3D structure with key phosphorylation sites and an updated overview of all so-far available mouse models to study ATF2 in vivo.

Czech Centre for Phenogenomics Institute of Molecular Genetics of the ASCR Prague Czech Republic

Experimental Tumorpathology Institute of Pathology University Hospital Erlangen Friedrich Alexander University Erlangen Nuremberg Erlangen Germany

Institute of Bioinformatics and Applied Biotechnology Biotech Park Electronic City Phase 1 Bangalore India

Zobrazit více v PubMed

Stepanenko A. A., Vassetzky Y. S. and Kavsan V. M (2013) Antagonistic functional duality of cancer genes. Gene, 529, 199–207. PubMed

Lopez-Bergami P., Lau E. and Ronai Z (2010) Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer, 10, 65–76. PubMed PMC

Kawasaki H., Schiltz L., Chiu R., Itakura K., Taira K., Nakatani Y. and Yokoyama K. K (2000) ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature, 405, 195–200. PubMed

Bhoumik A. and Ronai Z (2008) ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle, 7, 2341–2345. PubMed

Lau E. and Ronai Z. A (2012) ATF2 - at the crossroad of nuclear and cytosolic functions. J. Cell Sci., 125, 2815–2824. PubMed PMC

Watson G., Ronai Z. A. and Lau E (2017) ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol. Res., 119, 347–357. PubMed PMC

Gozdecka M. and Breitwieser W (2012) The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochem. Soc. Trans., 40, 230–234. PubMed

Bakin A. V., Rinehart C., Tomlinson A. K. and Arteaga C. L (2002) p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci., 115, 3193–3206. PubMed

Nam E. H., Lee Y., Moon B., Lee J. W. and Kim S (2015) Twist1 and AP-1 cooperatively upregulate integrin α5 expression to induce invasion and the epithelial-mesenchymal transition. Carcinogenesis, 36, 327–337. PubMed

Harper K. L., Sosa M. S., Entenberg D., et al. . (2016) Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature, 540, 588–592. PubMed PMC

Li S., Ezhevsky S., Dewing A., et al. (2010) Radiation sensitivity and tumor susceptibility in ATM phospho-mutant ATF2 mice. Genes Cancer, 1, 316–330. PubMed PMC

Lau E., Feng Y., Claps G., et al. (2015) The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. Sci. Signal., 8, ra124. PubMed PMC

Shah M., Bhoumik A., Goel V., et al. (2010) A role for ATF2 in regulating MITF and melanoma development. PLoS Genet., 6, e1001258. PubMed PMC

Claps G., Cheli Y., Zhang T., et al. . (2016) A transcriptionally inactive ATF2 variant drives melanomagenesis. Cell Rep., 15, 1884–1892. PubMed PMC

Reimold A. M., Grusby M. J., Kosaras B., et al. . (1996) Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. Nature, 379, 262–265. PubMed

Maekawa T., Bernier F., Sato M., et al. . (1999) Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome. J. Biol. Chem., 274, 17813–17819. PubMed

Ackermann J., Ashton G., Lyons S., James D., Hornung J. P., Jones N. and Breitwieser W (2011) Loss of ATF2 function leads to cranial motoneuron degeneration during embryonic mouse development. PLoS One, 6, e19090. PubMed PMC

Ozawa K., Sudo T., Soeda E., Yoshida M. C. and Ishii S (1991) Assignment of the human CREB2 (CRE-BP1) gene to 2q32. Genomics, 10, 1103–1104. PubMed

Nagadoi A., Nakazawa K., Uda H., Okuno K., Maekawa T., Ishii S. and Nishimura Y (1999) Solution structure of the transactivation domain of ATF-2 comprising a zinc finger-like subdomain and a flexible subdomain. J. Mol. Biol., 287, 593–607. PubMed

Li X. Y. and Green M. R (1996) Intramolecular inhibition of activating transcription factor-2 function by its DNA-binding domain. Genes Dev., 10, 517–527. PubMed

Liu F. and Green M. R (1990) A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell, 61, 1217–1224. PubMed

Zu Y. L., Takamatsu Y., Zhao M. J., Maekawa T., Handa H. and Ishii S (1992) Transcriptional regulation by a point mutant of adenovirus-2 E1a product lacking DNA binding activity. J. Biol. Chem., 267, 20181–20187. PubMed

Maguire H. F., Hoeffler J. P. and Siddiqui A (1991) HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science, 252, 842–844. PubMed

Wagner S. and Green M. R (1993) HTLV-I Tax protein stimulation of DNA binding of bZIP proteins by enhancing dimerization. Science, 262, 395–399. PubMed

Livingstone C., Patel G. and Jones N (1995) ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J., 14, 1785–1797. PubMed PMC

Sano Y., Tokitou F., Dai P., Maekawa T., Yamamoto T. and Ishii S (1998) CBP alleviates the intramolecular inhibition of ATF-2 function. J. Biol. Chem., 273, 29098–29105. PubMed

Hai T. W., Liu F., Coukos W. J. and Green M. R (1989) Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev., 3, 2083–2090. PubMed

Chatton B., Bocco J. L., Goetz J., Gaire M., Lutz Y. and Kedinger C (1994) Jun and Fos heterodimerize with ATFa, a member of the ATF/CREB family and modulate its transcriptional activity. Oncogene, 9, 375–385. PubMed

Vlahopoulos S. A., Logotheti S., Mikas D., Giarika A., Gorgoulis V. and Zoumpourlis V (2008) The role of ATF-2 in oncogenesis. Bioessays, 30, 314–327. PubMed

Hai T. and Curran T (1991) Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. USA, 88, 3720–3724. PubMed PMC

van Dam H. and Castellazzi M (2001) Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene, 20, 2453–2464. PubMed

Hayakawa J., Mittal S., Wang Y., et al. . (2004) Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol. Cell, 16, 521–535. PubMed

Ouwens D. M., de Ruiter N. D., van der Zon G. C., et al. . (2002) Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J., 21, 3782–3793. PubMed PMC

Chang L. and Karin M (2001) Mammalian MAP kinase signalling cascades. Nature, 410, 37–40. PubMed

Angel P., Hattori K., Smeal T. and Karin M (1988) The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell, 55, 875–885. PubMed

Takeda J., Maekawa T., Sudo T., Seino Y., Imura H., Saito N., Tanaka C. and Ishii S (1991) Expression of the CRE-BP1 transcriptional regulator binding to the cyclic AMP response element in central nervous system, regenerating liver, and human tumors. Oncogene, 6, 1009–1014. PubMed

Stein B., Angel P., van Dam H., Ponta H., Herrlich P., van der Eb A. and Rahmsdorf H. J (1992) Ultraviolet-radiation induced c-jun gene transcription: two AP-1 like binding sites mediate the response. Photochem. Photobiol., 55, 409–415. PubMed

van Dam H., Duyndam M., Rottier R., Bosch A., de Vries-Smits L., Herrlich P., Zantema A., Angel P. and van der Eb A. J (1993) Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J., 12, 479–487. PubMed PMC

van Dam H., Wilhelm D., Herr I., Steffen A., Herrlich P. and Angel P (1995) ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J., 14, 1798–1811. PubMed PMC

Liu H., Deng X., Shyu Y. J., Li J. J., Taparowsky E. J. and Hu C. D (2006) Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. EMBO J., 25, 1058–1069. PubMed PMC

Baan B., van Dam H., van der Zon G. C., Maassen J. A. and Ouwens D. M (2006) The role of c-Jun N-terminal kinase, p38, and extracellular signal-regulated kinase in insulin-induced Thr69 and Thr71 phosphorylation of activating transcription factor 2. Mol. Endocrinol., 20, 1786–1795. PubMed

Sevilla A., Santos C. R., Barcia R., Vega F. M. and Lazo P. A (2004) c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene, 23, 8950–8958. PubMed

Sakurai A., Maekawa T., Sudo T., Ishii S. and Kishimoto A (1991) Phosphorylation of cAMP response element-binding protein, CRE-BP1, by cAMP-dependent protein kinase and protein kinase C. Biochem. Biophys. Res. Commun., 181, 629–635. PubMed

Gupta S., Campbell D., Dérijard B. and Davis R. J (1995) Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science, 267, 389–393. PubMed

Baan B., van der Zon G. C., Maassen J. A. and Ouwens D. M (2009) The nuclear appearance of ERK1/2 and p38 determines the sequential induction of ATF2-Thr71 and ATF2-Thr69 phosphorylation by serum in JNK-deficient cells. Mol. Cell. Endocrinol., 311, 94–100. PubMed

Jia H., Cong Q., Chua J. F., et al. (2015) p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance. Oncogene, 34, 3568–3581. PubMed

Morton S., Davis R. J. and Cohen P (2004) Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett., 572, 177–183. PubMed

Ban N., Yamada Y., Someya Y., et al. (2000) Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. Diabetes, 49, 1142–1148. PubMed

Persengiev S. P. and Green M. R (2003) The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis, 8, 225–228. PubMed

Hamard P. J., Dalbies-Tran R., Hauss C., Davidson I., Kedinger C. and Chatton B (2005) A functional interaction between ATF7 and TAF12 that is modulated by TAF4. Oncogene, 24, 3472–3483. PubMed

Diring J., Camuzeaux B., Donzeau M., Vigneron M., Rosa-Calatrava M., Kedinger C. and Chatton B (2011) A cytoplasmic negative regulator isoform of ATF7 impairs ATF7 and ATF2 phosphorylation and transcriptional activity. PLoS One, 6, e23351. PubMed PMC

Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D. L., Ideker T. and Ronai Z. A (2012) PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell, 148, 543–555. PubMed PMC

Kawasaki H., Song J., Eckner R., Ugai H., Chiu R., Taira K., Shi Y., Jones N. and Yokoyama K. K (1998) p300 and ATF-2 are components of the DRF complex, which regulates retinoic acid- and E1A-mediated transcription of the c-jun gene in F9 cells. Genes Dev., 12, 233–245. PubMed PMC

Maekawa T., Sakura H., Kanei-Ishii C., Sudo T., Yoshimura T., Fujisawa J., Yoshida M. and Ishii S (1989) Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J., 8, 2023–2028. PubMed PMC

Yamasaki T., Takahashi A., Pan J., Yamaguchi N. and Yokoyama K. K (2009) Phosphorylation of activation transcription factor-2 at serine 121 by protein kinase C controls c-Jun-mediated activation of transcription. J. Biol. Chem., 284, 8567–8581. PubMed PMC

Sand J. M., Aziz M. H., Dreckschmidt N. E., Havighurst T. C., Kim K., Oberley T. D. and Verma A. K (2010) PKCepsilon overexpression, irrespective of genetic background, sensitizes skin to UVR-induced development of squamous-cell carcinomas. J. Invest. Dermatol., 130, 270–277. PubMed PMC

Gillespie S., Zhang X. D. and Hersey P (2005) Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol. Cancer Ther., 4, 668–676. PubMed

Abu-Hamad S., Arbel N., Calo D., Arzoine L., Israelson A., Keinan N., Ben-Romano R., Friedman O. and Shoshan-Barmatz V (2009) The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. J. Cell Sci., 122, 1906–1916. PubMed

Vega F. M., Sevilla A. and Lazo P. A (2004) p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. Mol. Cell. Biol., 24, 10366–10380. PubMed PMC

Valbuena A., Sanz-García M., López-Sánchez I., Vega F. M. and Lazo P. A (2011) Roles of VRK1 as a new player in the control of biological processes required for cell division. Cell. Signal., 23, 1267–1272. PubMed

Fuchs S. Y., Tappin I. and Ronai Z (2000) Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J. Biol. Chem., 275, 12560–12564. PubMed

Paull T. T. (2015) Mechanisms of ATM activation. Annu. Rev. Biochem., 84, 711–738. PubMed

Lovejoy C. A. and Cortez D (2009) Common mechanisms of PIKK regulation. DNA Repair (Amst)., 8, 1004–1008. PubMed PMC

Cho S. G., Bhoumik A., Broday L., Ivanov V., Rosenstein B. and Ronai Z (2001) TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage. Mol. Cell. Biol., 21, 8398–8413. PubMed PMC

Ikura T., Ogryzko V. V., Grigoriev M., Groisman R., Wang J., Horikoshi M., Scully R., Qin J. and Nakatani Y (2000) Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell, 102, 463–473. PubMed

Neuwald A. F., Aravind L., Spouge J. L. and Koonin E. V (1999) AAA+: a class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res., 9, 27–43. PubMed

Masson C., Menaa F., Pinon-Lataillade G., Frobert Y., Radicella J. P. and Angulo J. F (2001) Identification of KIN (KIN17), a human gene encoding a nuclear DNA-binding protein, as a novel component of the TP53-independent response to ionizing radiation. Radiat. Res., 156, 535–544. PubMed

Kanemaki M., Kurokawa Y., Matsu-ura T., Makino Y., Masani A., Okazaki K., Morishita T. and Tamura T. A (1999) TIP49b, a new RuvB-like DNA helicase, is included in a complex together with another RuvB-like DNA helicase, TIP49a. J. Biol. Chem., 274, 22437–22444. PubMed

Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N. and Ronai Z (2005) ATM-dependent phosphorylation of ATF2 is required for the DNA damage response. Mol. Cell, 18, 577–587. PubMed PMC

Raskov H., Pommergaard H. C., Burcharth J. and Rosenberg J (2014) Colorectal carcinogenesis–update and perspectives. World J. Gastroenterol., 20, 18151–18164. PubMed PMC

Maitra A. and Hruban R. H (2008) Pancreatic cancer. Annu. Rev. Pathol., 3, 157–188. PubMed PMC

Fearon E. R. and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759–767. PubMed

Botla S. K., Savant S., Jandaghi P., et al. . (2016) Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression. Cancer Res., 76, 4149–4159. PubMed

Lao V. V. and Grady W. M (2011) Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol., 8, 686–700. PubMed PMC

Raskov H., Soby J. H., Troelsen J., Bojesen R. D., and Gogenur I (2019) Driver gene mutations and epigenetics in colorectal cancer. Ann. Surg. PubMed

Toh T. B., Lim J. J. and Chow E. K (2017) Epigenetics in cancer stem cells. Mol. Cancer, 16, 29. PubMed PMC

Karanam B., Wang L., Wang D., Liu X., Marmorstein R., Cotter R. and Cole P. A (2007) Multiple roles for acetylation in the interaction of p300 HAT with ATF-2. Biochemistry, 46, 8207–8216. PubMed PMC

Zarour L. R., Anand S., Billingsley K. G., et al. . (2017) Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell. Mol. Gastroenterol. Hepatol., 3, 163–173. PubMed PMC

Chen C., Aihemaiti M., Zhang X., Qu H., Sun Q. L., He Q. S. and Yu W. B (2018) Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2. Am. J. Cancer Res., 8, 852–865. PubMed PMC

Eichhorn S. W., Guo H., McGeary S. E., et al. (2014) mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. Mol. Cell, 56, 104–115. PubMed PMC

Knowlton D. L., Tang K., Henstock P. V. and Subramanian R. R (2011) miRNA alterations modify kinase activation in the IGF-1 pathway and correlate with colorectal cancer stage and progression in patients. J. Cancer, 2, 490–502. PubMed PMC

Zhang S., Dong X., Ji T., Chen G. and Shan L (2017) Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer. Am. J. Transl. Res., 9, 366–375. PubMed PMC

Jung J., Yeom C., Choi Y. S., Kim S., Lee E., Park M. J., Kang S. W., Kim S. B. and Chang S (2015) Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge. Oncotarget, 6, 20370–20387. PubMed PMC

Song L., Peng L., Hua S., Li X., Ma L., Jie J., Chen D., Wang Y. and Li D (2018) miR-144-5p enhances the radiosensitivity of non-small-cell lung cancer cells via targeting ATF2. Biomed Res. Int., 2018, 5109497. PubMed PMC

Huang G., Pan J., Ye Z., Fang B., Cheng W. and Cao Z (2017) Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget, 8, 104206–104215. PubMed PMC

Jiang Y., Jiang J., Jia H., Qiao Z. and Zhang J (2018) Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun. Cell. Physiol. Biochem., 51, 129–141. PubMed

Tian L., Zhang J., Ren X., Liu X., Gao W., Zhang C., Sun Y. and Liu M (2017) Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2. Oncotarget, 8, 79023–79033. PubMed PMC

Sun X., Lou L., Zhong K. and Wan L (2017) MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. Exp. Biol. Med. (Maywood), 242, 1299–1305. PubMed PMC

Pu Y., Zhao F., Wang H. and Cai S (2017) MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci. Rep., 7, 44218. PubMed PMC

Lv G., Hu Z., Tie Y., Du J., Fu H., Gao X. and Zheng X (2014) MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. Oncol. Rep., 32, 1021–1028. PubMed

Arora H., Qureshi R., Park A. K. and Park W. Y (2011) Coordinated regulation of ATF2 by miR-26b in γ-irradiated lung cancer cells. PLoS One, 6, e23802. PubMed PMC

De Robertis M., Loiacono L., Fusilli C., et al. . (2017) Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer. Clin. Cancer Res., 23, 159–170. PubMed PMC

Lim H. J., Park M. N., Kim C., Kang B., Song H.S., Lee H., Kim S.H., Shim B.S., and Kim B (2019) MiR-657/ATF2 signaling pathway has a critical role in Spatholobus suberectus Dunn extract-induced apoptosis in U266 and U937 cells. Cancers (Basel), 11, 1–16. PubMed PMC

Zhang R., Luo H., Wang S., et al. . (2015) MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells. J. Neurooncol., 121, 63–72. PubMed

Hu Z., Tie Y., Lv G., Zhu J., Fu H. and Zheng X (2018) Transcriptional activation of miR-320a by ATF2, ELK1 and YY1 induces cancer cell apoptosis under ionizing radiation conditions. Int. J. Oncol., 53, 1691–1702. PubMed

Liu F., Cheng Z., Li X., Li Y., Zhang H., Li J., Liu F., Xu H. and Li F (2017) A novel Pak1/ATF2/miR-132 signaling axis is involved in the hematogenous metastasis of gastric cancer cells. Mol. Ther. Nucleic Acids, 8, 370–382. PubMed PMC

Xiao L., Rao J. N., Zou T., et al. (2007) Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells. Mol. Biol. Cell, 18, 4579–4590. PubMed PMC

Al-Sadi R., Guo S., Ye D., Dokladny K., Alhmoud T., Ereifej L., Said H. M. and Ma T. Y (2013) Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation. J. Immunol., 190, 6596–6606. PubMed PMC

Arana M. R., Tocchetti G. N., Domizi P., et al. . (2015) Coordinated induction of GST and MRP2 by cAMP in Caco-2 cells: role of protein kinase A signaling pathway and toxicological relevance. Toxicol. Appl. Pharmacol., 287, 178–190. PubMed

Namachivayam K., MohanKumar K., Arbach D., Jagadeeswaran R., Jain S. K., Natarajan V., Mehta D., Jankov R. P. and Maheshwari A (2015) All-trans retinoic acid induces TGF-β2 in intestinal epithelial cells via RhoA- and p38α MAPK-mediated activation of the transcription factor ATF2. PLoS One, 10, e0134003. PubMed PMC

Jia H., Cong Q., Chua J. F., et al. . (2015) p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance. Oncogene, 34, 3568–3581. PubMed

Voloshanenko O., Schwartz U., Kranz D., Rauscher B., Linnebacher M., Augustin I. and Boutros M (2018) β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells. Sci. Rep., 8, 3178. PubMed PMC

Han S. I., Yasuda K. and Kataoka K (2011) ATF2 interacts with beta-cell-enriched transcription factors, MafA, Pdx1, and beta2, and activates insulin gene transcription. J. Biol. Chem., 286, 10449–10456. PubMed PMC

Hay C. W., Ferguson L. A. and Docherty K (2007) ATF-2 stimulates the human insulin promoter through the conserved CRE2 sequence. Biochim. Biophys. Acta, 1769, 79–91. PubMed

Stoian M., State N., Stoica V. and Radulian G (2014) Apoptosis in colorectal cancer. J. Med. Life, 7, 160–164. PubMed PMC

Watson A. J. (2004) Apoptosis and colorectal cancer. Gut, 53, 1701–1709. PubMed PMC

Hanahan D. and Weinberg R. A (2011) Hallmarks of cancer: the next generation. Cell, 144, 646–674. PubMed

Zhang J. Y., Jiang H., Gao W., Wu J., Peng K., Shi Y. F. and Zhang X. J (2008) The JNK/AP1/ATF2 pathway is involved in H2O2-induced acetylcholinesterase expression during apoptosis. Cell. Mol. Life Sci., 65, 1435–1445. PubMed PMC

Salameh A., Galvagni F., Anselmi F., De Clemente C., Orlandini M. and Oliviero S (2010) Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J. Biol. Chem., 285, 23096–23104. PubMed PMC

Averous J., Bruhat A., Jousse C., Carraro V., Thiel G. and Fafournoux P (2004) Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation. J. Biol. Chem., 279, 5288–5297. PubMed

Berger A. J., Kluger H. M., Li N., Kielhorn E., Halaban R., Ronai Z. and Rimm D. L (2003) Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res., 63, 8103–8107. PubMed

Ronai Z., Yang Y. M., Fuchs S. Y., Adler V., Sardana M. and Herlyn M (1998) ATF2 confers radiation resistance to human melanoma cells. Oncogene, 16, 523–531. PubMed

Li M., Wu X., Liu N., Li X., Meng F. and Song S (2017) Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy. Cell Biol. Int., 41, 599–610. PubMed

Inoue S., Mizushima T., Ide H., Jiang G., Goto T., Nagata Y., Netto G. J. and Miyamoto H (2018) ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling. Endocr. Connect., 7, 1397–1408. PubMed PMC

Papassava P., Gorgoulis V. G., Papaevangeliou D., Vlahopoulos S., van Dam H. and Zoumpourlis V (2004) Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res., 64, 8573–8584. PubMed

Zoumpourlis V., Papassava P., Linardopoulos S., Gillespie D., Balmain A. and Pintzas A (2000) High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene, 19, 4011–4021. PubMed

Maekawa T., Shinagawa T., Sano Y., et al. . (2007) Reduced levels of ATF-2 predispose mice to mammary tumors. Mol. Cell. Biol., 27, 1730–1744. PubMed PMC

Su L., Sampaio A. V., Jones K. B., et al. . (2012) Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell, 21, 333–347. PubMed PMC

Gao Z., Shang Q., Liu Z., Deng C. and Guo C (2015) Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1. Oncotarget, 6, 36338–36353. PubMed PMC

Duffey D., Dolgilevich S., Razzouk S., Li L., Green R. and Gorti G. K (2011) Activating transcription factor-2 in survival mechanisms in head and neck carcinoma cells. Head Neck, 33, 1586–1599. PubMed PMC

Walluscheck D., Poehlmann A., Hartig R., et al. (2013) ATF2 knockdown reinforces oxidative stress-induced apoptosis in TE7 cancer cells. J. Cell. Mol. Med., 17, 976–988. PubMed PMC

Zhang G., Zhang J., Shang D., Qi B. and Chen H (2015) Deoxycholic acid inhibited proliferation and induced apoptosis and necrosis by regulating the activity of transcription factors in rat pancreatic acinar cell line AR42J. In Vitro Cell. Dev. Biol. Anim., 51, 851–856. PubMed

Mouratidis P. X., Colston K. W., Bartlett J. B., Muller G. W., Man H. W., Stirling D. and Dalgleish A. G (2009) Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells. Pancreas, 38, 78–84. PubMed

An J. J., Shi K. J., Wei W., et al. . (2013) The ROS/JNK/ATF2 pathway mediates selenite-induced leukemia NB4 cell cycle arrest and apoptosis in vitro and in vivo. Cell Death Dis., 4, e973. PubMed PMC

Bhoumik A., Huang T. G., Ivanov V., Gangi L., Qiao R. F., Woo S. L., Chen S. H. and Ronai Z (2002) An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J. Clin. Invest., 110, 643–650. PubMed PMC

Bhoumik A., Gangi L. and Ronai Z (2004) Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res., 64, 8222–8230. PubMed

Bhoumik A., Ivanov V. and Ronai Z (2001) Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin. Cancer Res., 7, 331–342. PubMed

Kalluri R. and Weinberg R. A (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420–1428. PubMed PMC

Spaderna S., Schmalhofer O., Hlubek F., Berx G., Eger A., Merkel S., Jung A., Kirchner T. and Brabletz T (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology, 131, 830–840. PubMed

Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L. A., Knuechel R. and Kirchner T (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA, 98, 10356–10361. PubMed PMC

Gui T., Sun Y., Shimokado A. and Muragaki Y (2012) The roles of mitogen-activated protein kinase pathways in TGF-β-induced epithelial-mesenchymal transition. J. Signal Transduct., 2012, 289243. PubMed PMC

Xu Y., Liu Z. and Guo K (2012) The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines. Pathol. Oncol. Res., 18, 571–577. PubMed

Yuanhong X., Feng X., Qingchang L., Jianpeng F., Zhe L. and Kejian G (2010) Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int. J. Biol. Markers, 25, 136–140. PubMed

Yu T., Li Y. J., Bian A. H., et al. . (2014) The regulatory role of activating transcription factor 2 in inflammation. Mediators Inflamm., 2014, 950472. PubMed PMC

Li M., Zhang D., Ge X., Zhu X., Zhou Y., Zhang Y., Peng X. and Shen A (2019) TRAF6-p38/JNK-ATF2 axis promotes microglial inflammatory activation. Exp. Cell Res., 376, 133–148. PubMed

Hu G., Zhao X., Wang C., et al. . (2017) MicroRNA-145 attenuates TNF-α-driven cartilage matrix degradation in osteoarthritis via direct suppression of MKK4. Cell Death Dis., 8, e3140. PubMed PMC

Reimold A. M., Kim J., Finberg R. and Glimcher L. H (2001) Decreased immediate inflammatory gene induction in activating transcription factor-2 mutant mice. Int. Immunol., 13, 241–248. PubMed

Desai S., Laskar S., and Pandey B. N (2014) Role of ATF-2 in regulation of epithelial–mesenchymal transition and radio-sensitivity of A549 cells mediated by secreted soluble factors. J Radiat Res., 55, i116–i117.

Huang Y., Miao Z., Hu Y., Yuan Y., Zhou Y., Wei L., Zhao K., Guo Q. and Lu N (2017) Baicalein reduces angiogenesis in the inflammatory microenvironment via inhibiting the expression of AP-1. Oncotarget, 8, 883–899. PubMed PMC

Lee S. H., Bahn J. H., Whitlock N. C. and Baek S. J (2010) Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene, 29, 5182–5192. PubMed PMC

Ivanov V. N. and Ronai Z (1999) Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells. J. Biol. Chem., 274, 14079–14089. PubMed

Wang T., Yu Q., Li J., et al. (2017) O-GlcNAcylation of fumarase maintains tumour growth under glucose deficiency. Nat. Cell Biol., 19, 833–843. PubMed

Lawrence M. C., Naziruddin B., Levy M. F., Jackson A. and McGlynn K (2011) Calcineurin/nuclear factor of activated T cells and MAPK signaling induce TNF-{alpha} gene expression in pancreatic islet endocrine cells. J. Biol. Chem., 286, 1025–1036. PubMed PMC

Ammendrup A., Maillard A., Nielsen K., Aabenhus Andersen N., Serup P., Dragsbaek Madsen O., Mandrup-Poulsen T. and Bonny C (2000) The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes, 49, 1468–1476. PubMed

Wu D. S., Chen C., Wu Z. J., et al. . (2016) ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma. J. Exp. Clin. Cancer Res., 35, 108. PubMed PMC

You Z., Zhou Y., Guo Y., Chen W., Chen S. and Wang X (2016) Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma. Oncol. Lett., 11, 760–766. PubMed PMC

Zhou H., Cai L., Zhang X., Li A., Miao Y., Li Q., Qiu X. and Wang E (2018) ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients. Lab. Invest., 98, 670–681. PubMed

Zheng R., Liu Q., Wang T., Wang L. and Zhang Y (2018) FAM98A promotes proliferation of non-small cell lung cancer cells via the P38-ATF2 signaling pathway. Cancer Manag. Res., 10, 2269–2278. PubMed PMC

Chen S. Y., Takeuchi S., Moroi Y., et al. (2009) Concordant overexpression of phosphorylated ATF2 and STAT3 in extramammary Paget’s disease. J. Cutan. Pathol., 36, 402–408. PubMed

Rudraraju B., Droog M., Abdel-Fatah T. M., et al. (2014) Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Res. Treat., 147, 295–309. PubMed

Pradhan M. P., Prasad N. K. and Palakal M. J (2012) A systems biology approach to the global analysis of transcription factors in colorectal cancer. BMC Cancer, 12, 331. PubMed PMC

Cerami E., Gao J., Dogrusoz U., et al. . (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov., 2, 401–404. PubMed PMC

Gao J., Aksoy B. A., Dogrusoz U., et al. . (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6, pl1. PubMed PMC

Breitwieser W., Lyons S., Flenniken A. M., Ashton G., Bruder G., Willington M., Lacaud G., Kouskoff V. and Jones N (2007) Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev., 21, 2069–2082. PubMed PMC

Bhoumik A., Fichtman B., Derossi C., et al. . (2008) Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc. Natl. Acad. Sci. USA, 105, 1674–1679. PubMed PMC

Gozdecka M., Lyons S., Kondo S., Taylor J., Li Y., Walczynski J., Thiel G., Breitwieser W. and Jones N (2014) JNK suppresses tumor formation via a gene-expression program mediated by ATF2. Cell Rep., 9, 1361–1374. PubMed

Bhoumik A., Jones N. and Ronai Z (2004) Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc. Natl. Acad. Sci. USA, 101, 4222–4227. PubMed PMC

Abbas S., Bhoumik A., Dahl R., Vasile S., Krajewski S., Cosford N. D. and Ronai Z. A (2007) Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res., 13, 6769–6778. PubMed PMC

Graziani G., Artuso S., De Luca A., et al. (2015) A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem. Pharmacol., 95, 16–27. PubMed

The UniProt Consortium. (2019) UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res., 47, D506–D515. PubMed PMC

Webb B. and Sali A (2016) Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinformatics, 54, 5.6.1–5.6.37. PubMed PMC

Sali A. and Blundell T. L (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol., 234, 779–815. PubMed

Wu S. and Zhang Y (2008) MUSTER: improving protein sequence profile-profile alignments by using multiple sources of structure information. Proteins, 72, 547–556. PubMed PMC

Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C. and Ferrin T. E (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem., 25, 1605–1612. PubMed

Giannakis M., Mu X. J., Shukla S. A., et al. . (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep., 15, 857–865. PubMed PMC

Seshagiri S., Stawiski E. W., Durinck S., et al. . (2012) Recurrent R-spondin fusions in colon cancer. Nature, 488, 660–664. PubMed PMC

Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330–337. PubMed PMC

Liu J., Lichtenberg T., Hoadley K. A., et al. ; Cancer Genome Atlas Research Network (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell, 173, 400–416.e11. PubMed PMC

Brannon A. R., Vakiani E., Sylvester B. E., et al. . (2014) Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol., 15, 454. PubMed PMC

Yaeger R., Chatila W. K., Lipsyc M. D., et al. . (2018) Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell, 33, 125–136.e3. PubMed PMC

Guda K., Veigl M. L., Varadan V., et al. . (2015) Novel recurrently mutated genes in African American colon cancers. Proc. Natl. Acad. Sci. USA, 112, 1149–1154. PubMed PMC

Jiao Y., Yonescu R., Offerhaus G. J., et al. . (2014) Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J. Pathol., 232, 428–435. PubMed PMC

Biankin A. V., Waddell N., Kassahn K. S., et al. .; Australian Pancreatic Cancer Genome Initiative (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491, 399–405. PubMed PMC

Bailey P., Chang D. K., Nones K., et al. ; Australian Pancreatic Cancer Genome Initiative (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531, 47–52. PubMed

Hoadley K. A., Yau C., Hinoue T., et al. .; Cancer Genome Atlas Network (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell, 173, 291–304.e6. PubMed PMC

Witkiewicz A. K., McMillan E. A., Balaji U., et al. . (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun., 6, 6744. PubMed PMC

ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2